Barone D, Assandri A, Galliani G, Glässer A, Tarzia G
J Pharm Pharmacol. 1985 Mar;37(3):180-7. doi: 10.1111/j.2042-7158.1985.tb05036.x.
The binding of [3H]zetidoline, a novel neuroleptic agent, to rat brain striatal membranes was investigated in-vitro. The optimal binding conditions for [3H]zetidoline differed from those for [3H]spiperone in pH, temperature and time. [3H]Zetidoline has high affinity for striatal dopamine receptors. Its binding is saturable, stereo-specific, has a low non-specific component and is reversible and tissue specific. The Scatchard analysis gave a biphasic curve, indicating that [3H]zetidoline interacts with more than one population of receptor sites (B'max = 67 fmol mg-1 protein, K'd = 0.11 nM; B"max = 500 fmol mg-1 protein, K'd = 2.49 nM). Kinetic analysis of rates of association and dissociation yielded a Kd value in agreement with that measured at equilibrium. Inhibition studies indicated that only dopamine and dopaminergic agents are able to displace [3H]zetidoline from its binding sites, and in a different rank order from that for displacement of [3H]spiperone. (-)-Sulpiride was especially effective in inhibiting [3H]zetidoline specific binding. Furthermore, like that of [3H]benzamides, [3H]zetidoline binding appears to be highly Na+-dependent and Li+ only partially substitutes Na+.
对新型抗精神病药物[3H]泽替多林与大鼠脑纹状体膜的结合进行了体外研究。[3H]泽替多林的最佳结合条件在pH、温度和时间方面与[3H]螺哌隆的不同。[3H]泽替多林对纹状体多巴胺受体具有高亲和力。其结合具有饱和性、立体特异性、非特异性成分低、可逆且具有组织特异性。Scatchard分析得到一条双相曲线,表明[3H]泽替多林与不止一种受体位点群体相互作用(B'max = 67 fmol mg-1蛋白质,K'd = 0.11 nM;B"max = 500 fmol mg-1蛋白质,K'd = 2.49 nM)。结合和解离速率的动力学分析得出的Kd值与平衡时测得的值一致。抑制研究表明,只有多巴胺和多巴胺能药物能够将[3H]泽替多林从其结合位点上置换下来,且置换顺序与[3H]螺哌隆的不同。(-)-舒必利在抑制[3H]泽替多林特异性结合方面特别有效。此外,与[3H]苯甲酰胺一样,[3H]泽替多林的结合似乎高度依赖Na+,Li+只能部分替代Na+。